232 related articles for article (PubMed ID: 27697770)
41. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
[TBL] [Abstract][Full Text] [Related]
43. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
[TBL] [Abstract][Full Text] [Related]
44. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
45. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
46. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
47. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Cheson BD; Mato AR
Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
[TBL] [Abstract][Full Text] [Related]
48. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
49. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
Buccisano F; Maurillo L; Gattei V; Del Poeta G; Del Principe MI; Cox MC; Panetta P; Consalvo MI; Mazzone C; Neri B; Ottaviani L; Fraboni D; Tamburini A; Lo-Coco F; Amadori S; Venditti A
Leukemia; 2006 Oct; 20(10):1783-9. PubMed ID: 16838027
[TBL] [Abstract][Full Text] [Related]
50. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis.
Suzuki K; Nishiwaki K; Nagao R; Katori M; Fukushima R; Hattori D; Masuoka H; Yano S
Int J Hematol; 2021 Nov; 114(5):599-607. PubMed ID: 34339005
[TBL] [Abstract][Full Text] [Related]
52. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma.
Wang J; Li J; Zhang R; Li J; Chen L; Jin Y
Discov Oncol; 2024 Feb; 15(1):38. PubMed ID: 38367151
[TBL] [Abstract][Full Text] [Related]
53. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
54. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
55. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Hillmen P
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
[TBL] [Abstract][Full Text] [Related]
56. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia.
Maloum K; Charlotte F; Divine M; Cazin B; Lesty C; Merle-Béral H;
Haematologica; 2006 Jun; 91(6):860-1. PubMed ID: 16769593
[TBL] [Abstract][Full Text] [Related]
57. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.
Esteve J; Villamor N; Colomer D; Cervantes F; Campo E; Carreras E; Montserrat E
Leukemia; 2001 Mar; 15(3):445-51. PubMed ID: 11237069
[TBL] [Abstract][Full Text] [Related]
58. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract][Full Text] [Related]
59. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
[TBL] [Abstract][Full Text] [Related]
60. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
Avet-Loiseau H; Ludwig H; Landgren O; Paiva B; Morris C; Yang H; Zhou K; Ro S; Mateos MV
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e30-e37. PubMed ID: 31780415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]